

Follow us on :



Contents

- [News and Commentary](#)
- [Media Releases](#)
- [Latest Research](#)
- [The Industry](#)
- [Leading Companies in the Industry](#)

AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

14 September 2021

Acquisdata Podcast – Gary J Phillips, CEO Pharmaxis Ltd. (ASX: PXS), 29/4/2020 – COVID 19 response

Gary Phillips, Pharmaxis CEO, discusses ensuring continuity of supply of its products throughout the crisis, the timeframe for trials of its unique anti-fibrotic treatment for a rare bone cancer, broader impacts for biopharma research and trials, the opportunity for the global industry and the potential for PXS respiratory products in the clinical aftermath of COVID -19.

<https://youtu.be/hgJkNOBbsqc>

This Week's News

- **GlobeNewswire - FDA Approves Phase II Kidney Cancer Therapy Study - 14/9/2021**

The STARLITE 2 study is a single arm, investigator-led Phase II study in patients with advanced clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.

For the complete story, see: <https://www.globenewswire.com/news-release/2021/09/13/2296227/0/en/FDA-Approves-Phase-II-Kidney-Cancer-Therapy-Study.html>

- **Herald Sun - Melbourne council's plan to grow cannabis - 14/9/2021**

A council in Melbourne's west has unveiled a plan to grow and sell medicinal cannabis to help boost its coffers.

For the complete story, see: https://www.heraldsun.com.au/subscribe/news/1/?sourceCode=HSWEB_WRE170_a_GGL&dest=https%3A%2F%2Fwww.heraldsun.com.au%2Fnews%2Fvictoria%2Fcouncils-plan-to-grow-and-sell-cannabis%2Fnews-story%2Fd6e80a16d980587539a8e9ba75975dfc&memtype=anonymous&mode=premium&v21=dynamic-cold-control-noscore&V21spcbehaviour=append

- **7NEWS.com.au - Moderna vaccine bookings about to open in Australia as supplies arrive from next week - 10/9/2021**

Bookings are about to open for Australia's newest vaccine, Moderna.

For the complete story, see: <https://7news.com.au/lifestyle/health-wellbeing/moderna-vaccine-bookings-about-to-open-in-australia-as-supplies-arrive-from-next-week-c-3929189>

Other Stories

- The Pharma Letter - New plan could shake up pricing and HTA process in Australia - 7/9/2021
- GlobeNewswire - Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response - 7/9/2021
- Startup Daily - Australia's first biotech incubator is happening thanks to a \$40 million grant - 7/9/2021
- Australian Government Department of Health - Landmark new medicines agreements to bring significant benefits for Australian patients - 7/9/2021
- Cosmos Magazine - Fertility clinics reap rich payments from pharmaceutical companies - 6/9/2021

Media Releases

- Acrux Limited (ASX: ACR) - Acrux's fifth generic dossier accepted by FDA for review - 13/9/2021
- Neuren Pharmaceuticals Limited (ASX: NEU) - Neuren completes placement to accelerate NNZ-2591 across 4 indications - 13/9/2021

NO.: 28377



AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

- Benitec Biopharma Limited (ASX: BLT) - Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022 - 8/9/2021

Latest Research

- Transdisciplinary research and clinical priorities for better health - By Luigi Fontana ,Alessio Fasano,Yap Seng Chong,Paolo Vineis,Walter C. Willett

Overviews of Leading Companies

Acrux Limited (ASX: ACR)

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE)

Benitec Biopharma Limited (ASX: BLT)

Bionomics Limited (ASX: BNO, OTCQX: BNOEF)

Clinuvel Pharmaceuticals Limited (ASX: CUV)

CSL Limited (ASX: CSL)

Genera Biosystems Limited

IDT Australia Limited (ASX: IDT)

Immutep Limited (ASX: IMM, NASDAQ: IMMMP)

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)

Mayne Pharma Group Limited (ASX: MYX)

Medical Developments International Limited (ASX: MVP)

Medlab Clinical Limited (ASX: MDC)

Mesoblast Limited (ASX: MSB; NASDAQ: MESO)

MMJ Group Holdings Limited (ASX: MMJ)

Monash IVF Group (ASX: MVF)

Neuren Pharmaceuticals Limited (ASX: NEU)

Palla Pharma Limited (ASX: PAL)

Pharmaxis Limited (ASX: PXS)

PolyNovo Limited (ASX: PNV)

Sirtex Medical Limited

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY)

Viralytics Limited (NYSE: MRK)

Vita Life Sciences Limited (ASX: VLS)

Senior Associate: Joseph Hang Ellision

NO.: 28377



AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

Are you MIFID II ready? You might like to talk to Acquisdata about our Bespoke Research offering. www.acquisdata.com/bespoke-research

Looking for
more in-depth
research ?



We also produce in-depth reports on a range of newly emerging market sectors. See our sister company's website at www.macrosourcemedia.com

Topics include: Deep Sea Mining, Fintech, Robotics, Smart City Technologies, High-Tech Shipping, UAV (drones), Internet of Things, Cybersecurity, Artificial Intelligence Software and more.

Acquisdata InView

Latest Version

Acquisdata InView - BioPharma - June 2019

<https://www.docdroid.net/5PeNs6Y/acquisdata-inview-biopharma-dr-peter-french-june-2019.pdf>

Dr Peter French, Biotechnology Consultant, speaks with Acquisdata's Fiona Fox about superbugs, bacteriophage and CRISPR gene-editing technology and biopharma companies working in this space.

View the playlist on Acquisdata's YouTube channel here:

<https://www.youtube.com/playlist?list=PLLht7jPps2v2runHsQivr-ANhIKQ9Zy-v>

Earlier Biopharma InViews:

Acquisdata InView - Biopharma - August 2018 (Topic: cancer diagnostics)

http://www.reportaldata.com/video/InView_BioPharma_201809/Acquisdata%20InView%20-%20BioPharma%20-%20Dr%20Peter%20French%20August%202018.pdf

View the playlist here: <https://www.youtube.com/playlist?list=PLLht7jPps2v1i9AyH4yJbFsATaAq8eYNx>

ABOUT InView

Learn from industry experts with Acquisdata InView. The latest addition to the Acquisdata suite of information products, Acquisdata InView features interviews with experts across a range of industries on topical issues.

Acquisdata is excited to connect with experts from across the world for InView. InView also opens the way for more in-depth Executive Snapshot interviews with company executives for their perspective on what's happening in their company and industry.

Coming up next will be Defence Expert, Rowan Moffitt, to give his view on developments in the defence and armaments industry for Acquisdata InView - Defence.

Acquisdata InView is available via the Acquisdata website, Reuters Eikon and Acquisdata's extensive network of distributors.

Industry SnapShots

Published by Acquisdata Pty Ltd

A.C.N. 147 825 536

ISSN 2203-2738 (Electronic)

©Acquisdata Pty Ltd 2021

www.acquisdata.com

Disclaimer of Warranties and Liability

Due to the number of sources from which the information and services on the Acquisdata Pty Ltd Service are obtained, and the inherent hazards of electronic distribution, there may be delays, omissions or inaccuracies in such information and services. Acquisdata Pty Ltd and its affiliates, agents, sales representatives, distributors, and licensors cannot and do not warrant the accuracy, completeness, currentness, merchant ability or fitness for a particular purpose of the information or services available through the Acquisdata Pty Ltd service. In no event will Acquisdata Pty Ltd, its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any loss or injury caused in whole or part by contingencies beyond its control in procuring, compiling, interpreting, editing, writing, reporting or delivering any information or services through the Acquisdata Pty Ltd Service. In no event will Acquisdata Pty Ltd or its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any decision made or action taken by licensee in reliance upon such information or services or for any consequential, special or similar damages, even if advised of the possibility of such damages. licensee agrees that the liability of Acquisdata Pty Ltd, its affiliates, agents, sales representatives, distributors and licensors, if any, arising out of any kind of legal claim (whether in contract, tort or otherwise) in any way connected with the Acquisdata Pty Ltd service shall not exceed the amount licensee paid for the use of the Acquisdata Pty Ltd service in the twelve (12) months immediately preceding the event giving rise to such claim.